Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lyrica adds third indication

Executive Summary

Pfizer's Lyrica (pregabalin) clears FDA June 10 for treatment of partial onset seizures. The Neurontin follow-on was approved for diabetic peripheral neuropathy and postherpetic neuralgia in December 2004 (1"The Pink Sheet" Jan. 10, 2005, p. 5). Lyrica's launch is awaiting final Drug Enforcement Agency scheduling. Pfizer says pregabalin will be available in pharmacies in the fall...

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts